3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
tremelimumab
×
90 days
×
Clear all
No trials found.